Compare Stocks: VIR, IONS, ALKS, and IMVT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$40.61 +1.2%	$45.93	$27.00 ▼ $55.67	$6.81B	0.32	2.60 million shs	1.63 million shs
IMVT Immunovant	$30.47 +0.7%	$38.41	$16.59 ▼ $45.42	$6.29B	0.84	1.61 million shs	1.49 million shs
IONS Ionis Pharmaceuticals	$45.28 +4.6%	$52.94	$42.63 ▼ $86.74	$7.52B	0.38	4.26 million shs	4.86 million shs
VIR Vir Biotechnology	$11.70 +5.2%	$10.47	$4.82 ▼ $12.00	$1.98B	1.59	2.36 million shs	1.97 million shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-2.73%	-11.93%	-21.81%	+28.88%
IMVT Immunovant	0.00%	-9.37%	-20.03%	-23.27%	+89.49%
IONS Ionis Pharmaceuticals	0.00%	+4.00%	-18.63%	-22.27%	-35.28%
VIR Vir Biotechnology	0.00%	+4.74%	+10.59%	+17.47%	+93.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$40.61 +1.2%	$45.93	$27.00 ▼ $55.67	$6.81B	0.32	2.60 million shs	1.63 million shs
IMVT Immunovant	$30.47 +0.7%	$38.41	$16.59 ▼ $45.42	$6.29B	0.84	1.61 million shs	1.49 million shs
IONS Ionis Pharmaceuticals	$45.28 +4.6%	$52.94	$42.63 ▼ $86.74	$7.52B	0.38	4.26 million shs	4.86 million shs
VIR Vir Biotechnology	$11.70 +5.2%	$10.47	$4.82 ▼ $12.00	$1.98B	1.59	2.36 million shs	1.97 million shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-2.73%	-11.93%	-21.81%	+28.88%
IMVT Immunovant	0.00%	-9.37%	-20.03%	-23.27%	+89.49%
IONS Ionis Pharmaceuticals	0.00%	+4.00%	-18.63%	-22.27%	-35.28%
VIR Vir Biotechnology	0.00%	+4.74%	+10.59%	+17.47%	+93.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.74	Moderate Buy	$54.47	34.13% Upside
IMVT Immunovant	2.58	Moderate Buy	$44.00	44.40% Upside
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$89.20	97.00% Upside
VIR Vir Biotechnology	2.67	Moderate Buy	$21.86	86.81% Upside

Current Analyst Ratings Breakdown

Latest VIR, IONS, ALKS, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/7/2026	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $22.00
10/6/2026	VIR Vir Biotechnology	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
10/2/2026	IMVT Immunovant	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/2/2026	VIR Vir Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/28/2026	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy
9/24/2026	IMVT Immunovant	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Positive
9/24/2026	IONS Ionis Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$85.00
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$50.00
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$50.00
9/24/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.48B	4.62	$1.67 per share	24.25	$11.02 per share	3.69
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
IONS Ionis Pharmaceuticals	$944M	7.97	N/A	N/A	$3.02 per share	14.99
VIR Vir Biotechnology	$68.56M	28.88	N/A	N/A	$5.50 per share	2.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	106.87	169.21	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
VIR Vir Biotechnology	-$437.99M	-$1.86	N/A	N/A	N/A	N/A	-29.99%	-23.62%	11/4/2026 (Estimated)

Latest VIR, IONS, ALKS, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	IONS Ionis Pharmaceuticals	-$1.21	N/A	N/A	N/A	$183.13 million	N/A
11/4/2026	Q3 2026	VIR Vir Biotechnology	-$0.7393	N/A	N/A	N/A	$0.87 million	N/A
10/28/2026	Q3 2026	ALKS Alkermes	-$0.0788	N/A	N/A	N/A	$463.35 million	N/A
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/5/2026	Q2 2026	VIR Vir Biotechnology	$0.3326	$0.47	+$0.1374	$0.47	$135.88 million	$238.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
IMVT Immunovant	N/A	7.27	7.27
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
VIR Vir Biotechnology	N/A	6.04	6.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
IMVT Immunovant	47.08%
IONS Ionis Pharmaceuticals	93.86%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
IMVT Immunovant	1.90%
IONS Ionis Pharmaceuticals	1.81%
VIR Vir Biotechnology	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
IMVT Immunovant	315	206.55 million	202.63 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
VIR Vir Biotechnology	367	169.22 million	164.31 million	Optionable

VIR, IONS, ALKS, and IMVT Headlines

Recent News About These Companies

HC Wainwright Has Pessimistic Opinion of VIR FY2028 Earnings

October 11 at 1:13 AM | americanbankingnews.com

VIR-5500 Receives FDA Fast Track Designation for Late-Line Metastatic CRPC

October 10 at 9:50 AM | cancernetwork.comC

Vir Biotechnology’s T-cell engager ‘VIR-5500’ gets US FDA’s fast track designation to treat prostate cancer

October 10 at 9:50 AM | pharmabiz.comP

Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year High - What's Next?

October 10 at 3:41 AM | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High - Here's What Happened

October 10 at 3:39 AM | marketbeat.com

Prostate and Rare Cancer Agents Nab FDA Fast Track Status

October 9 at 6:47 PM | targetedonc.comT

Chutes & Ladders—Vir looks to Liu to lead late-stage push

October 9 at 6:47 PM | fiercebiotech.comF

Vir Biotechnology stock hits 52-week high at 11.96 USD

October 9 at 6:47 PM | ca.investing.com

Vir Biotechnology (NASDAQ:VIR) Shares Climb 6.1% - Here's Why

October 9 at 11:59 AM | marketbeat.com

Vir Biotechnology, Inc. Announces Appointment of David Liu as Executive Vice President and Chief Medical Officer, Effective October 12, 2026

October 9 at 8:46 AM | marketscreener.comM

Vir Biotechnology, Inc. and Astellas Pharma Inc. Announce FDAFast Track Designation for PSMA-Targeted Pro-XTEN® Dual-Masked T-Cell Engager VIR-5500 for the Treatment of ...

October 9 at 8:46 AM | marketscreener.comM

Vir Biotechnology's VIR-5500 Gets FDA Fast Track Designation for Prostate Cancer

October 9 at 8:46 AM | finance.yahoo.com

What is HC Wainwright's Forecast for VIR FY2028 Earnings?

October 9 at 6:56 AM | marketbeat.com

HC Wainwright Forecasts Strong Price Appreciation for Vir Biotechnology (NASDAQ:VIR) Stock

October 9 at 2:36 AM | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Shares Down 6.5% - Here's What Happened

October 8 at 12:39 PM | marketbeat.com

How Upcoming SOLSTICE Phase 2 HDV Data Could Shape Vir Biotechnology’s (VIR) Investment Narrative

October 8 at 7:42 AM | finance.yahoo.com

Vir Biotechnology (NASDAQ:VIR) Stock Rating Lowered by Zacks Research

October 8 at 6:06 AM | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Cut to "Strong Sell" at Zacks Research

October 8 at 6:05 AM | marketbeat.com

uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Financial Survey

October 8 at 4:15 AM | americanbankingnews.com

Vir Biotechnology stock gained 5.46 percent before SOLSTICE data

October 7, 2026 | ad-hoc-news.deA

Vir Biotechnology appoints David Liu as chief medical officer

October 7, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VIR, IONS, ALKS, and IMVT Company Descriptions

Alkermes NASDAQ:ALKS

$40.61 +0.50 (+1.25%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$40.64 +0.03 (+0.07%)

As of 10/9/2026 07:30 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Immunovant NASDAQ:IMVT

$30.47 +0.21 (+0.69%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$30.48 +0.01 (+0.02%)

As of 10/9/2026 07:30 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Ionis Pharmaceuticals NASDAQ:IONS

$45.28 +1.98 (+4.57%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$45.08 -0.20 (-0.44%)

As of 10/9/2026 07:55 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Vir Biotechnology NASDAQ:VIR

$11.70 +0.58 (+5.22%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$11.62 -0.08 (-0.67%)

As of 10/9/2026 07:56 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VIR, IONS, ALKS, and IMVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VIR, IONS, ALKS, and IMVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VIR, IONS, ALKS, and IMVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VIR, IONS, ALKS, and IMVT Company Descriptions

Alkermes NASDAQ:ALKS

Immunovant NASDAQ:IMVT

Ionis Pharmaceuticals NASDAQ:IONS

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VIR, IONS, ALKS, and IMVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VIR, IONS, ALKS, and IMVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VIR, IONS, ALKS, and IMVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VIR, IONS, ALKS, and IMVT Company Descriptions

Alkermes NASDAQ:ALKS

Immunovant NASDAQ:IMVT

Ionis Pharmaceuticals NASDAQ:IONS

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools